AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ORPEA

Legal Proceedings Report Aug 2, 2022

1578_iss_2022-08-02_9691ffbf-ff12-461b-bc30-f3dd79ded9f3.pdf

Legal Proceedings Report

Open in Viewer

Opens in native device viewer

PRESS RELEASE FOLLOWING THE RECEIPT OF A FORMAL NOTICE FROM THE

CAISSE NATIONALE DE SOLIDARITÉ POUR L'AUTONOMIE

Puteaux, August 2, 2022 (20:00 CEST)

The Company indicates that it has received a formal notice from the Caisse nationale de solidarité pour l'autonomie (French National Solidarity Fund for Autonomy - CNSA) to return unduly received funding, dated July 29, 2022, following the report of the joint IGAS-IGF mission, in the amount of €55.8 million.

ORPEA will reimburse the amounts that were inappropriately recorded.

The Company's position to date is disclosed in note 3.11 to the 2021 consolidated financial statements, available in the Company's 2021 Universal Registration Document.

For the amounts that are subject to differences of assessment between ORPEA and the general inspections, ORPEA will provide its answers to the CNSA within the given timeframe. ORPEA will reimburse the amounts that were inappropriately recorded.

About ORPEA

ORPEA is a leading global player, expert in the care of all types of frailty. The Group operates in 22 countries and covers three core businesses: care for the elderly (nursing homes, assisted living, home care), post-acute and rehabilitation care and mental health care (specialized clinics). It has more than 71,000 employees and welcomes more than 255,000 patients and residents each year.

https://www.orpea-group.com/

ORPEA is listed on Euronext Paris (ISIN: FR0000184798) and is a member of the SBF 120, STOXX 600 Europe, MSCI Small Cap Europe and CAC Mid 60 indices.

ORPEA NewCap Image 7 Benoit Lesieur Dusan Oresansky Laurence Heilbronn Investor Relations Director Tel.: +33 (0)1 44 71 94 94 Tel.: +33 (0)6 89 87 61 37 [email protected] [email protected] [email protected]

Investor Relations Investor Relations Media Relations

Talk to a Data Expert

Have a question? We'll get back to you promptly.